Trial Profile

Phase IIb study of sapacitabine in older patients with myelodysplastic syndrome who have failed prior hypomethylating agent therapy

Status: Planning

Phase of Trial: Phase II

Latest Information Update: 15 Jan 2016

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Sapacitabine (Primary)
Indications Myelodysplastic syndromes
Focus Therapeutic Use
Sponsors Cyclacel Pharmaceuticals

Most Recent Events

11 Jan 2016 As per a Cyclacel media release, the company expects to start this trial in 2016.
11 Nov 2014 New trial record

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com